Sparrow BioAcoustics Announces the Launch of Stethophone™ – Bringing the Future of Personalized Heart Care Closer to Home

Stethophone™ by Sparrow BioAcoustics

Sparrow BioAcoustics [Sparrow], a pioneer in the field of bioacoustics technology, announces the launch of Stethophone™, a groundbreaking advancement in personalized heart health, exclusively on Valentine’s Day, February 14, 2024. This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location.

Built-in Microphone

Stethophone works by harnessing the built-in microphone of a smartphone to capture the nuanced sounds of the heart. Through sophisticated bioacoustics engineering, these sounds are then filtered to provide clear, medical-grade diagnostic signals – some of them at the outermost edges of human auditory perception. With widespread adoption, it is anticipated that this bioacoustics technology will allow for the detection and diagnosis of routine and difficult cardiac conditions sooner and with more ease.

FDA Clearance

An an unprecedented move, Stethophone recently won FDA clearance in 2023 for use by medical professionals in the United States, marking it as the first-ever FDA-cleared smartphone stethoscope Software-as-a-Medical-Device (SaMD). Furthermore, the software has achieved another landmark by obtaining FDA clearance, again in 2023, for use by consumers – another first in the industry – empowering individuals to take an active role in their heart health.

In addition to providing the sophisticated bioacoustics technology that powers Stethophone, Sparrow offers medical practitioners advanced visualizations that enable them to understand how to interpret the diagnostics originating from the device. These visualizations aid in the recognition of patterns and anomalies that may not be easily discernible by conventional cardiac diagnostics, thereby potentially enhancing today’s diagnostic accuracy and efficiency.

Mark Attila Opauzsky, CEO of Sparrow BioAcoustics

“We are at the forefront of a revolution in personalized heart health. Stethophone embodies our commitment to provide everyone the power, agency and access to fight heart disease right in their own hands. Launching on Valentine’s Day symbolizes our dedication to heart health and the love and care we invest in our products and the people they serve.” Valentine’s Day also marks the five-year anniversary when Mark almost lost his life to a sudden, rare disease. To him, this launch is very personal.

Future

As Sparrow eagerly celebrates the release of Stethophone, the company is already looking toward the future with the development of the next iteration of Stethophone, which explores integrating artificial intelligence functionalities into the bioacoustics engineering.

Stethophone is available now on iOS. To learn more about Stethophone and Sparrow BioAcoustics, please visit https://stethophone.com/.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”